GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » iRhythm Technologies Inc (NAS:IRTC) » Definitions » Intrinsic Value: Projected FCF

iRhythm Technologies (iRhythm Technologies) Intrinsic Value: Projected FCF : $-15.40 (As of Apr. 27, 2024)


View and export this data going back to 2016. Start your Free Trial

What is iRhythm Technologies Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-04-27), iRhythm Technologies's Intrinsic Value: Projected FCF is $-15.40. The stock price of iRhythm Technologies is $111.91. Therefore, iRhythm Technologies's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for iRhythm Technologies's Intrinsic Value: Projected FCF or its related term are showing as below:

IRTC's Price-to-Projected-FCF is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.67
* Ranked among companies with meaningful Price-to-Projected-FCF only.

iRhythm Technologies Intrinsic Value: Projected FCF Historical Data

The historical data trend for iRhythm Technologies's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

iRhythm Technologies Intrinsic Value: Projected FCF Chart

iRhythm Technologies Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - -9.17 -12.02 -15.40

iRhythm Technologies Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -12.02 -13.45 -14.43 -14.49 -15.40

Competitive Comparison of iRhythm Technologies's Intrinsic Value: Projected FCF

For the Medical Devices subindustry, iRhythm Technologies's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


iRhythm Technologies's Price-to-Projected-FCF Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, iRhythm Technologies's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where iRhythm Technologies's Price-to-Projected-FCF falls into.



iRhythm Technologies Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get iRhythm Technologies's Free Cash Flow(6 year avg) = $-50.84.

iRhythm Technologies's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Dec23)*0.8)/Shares Outstanding (Diluted Average)
=(12.608723088515*-50.83584+210.097*0.8)/30.702
=-15.40

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRhythm Technologies  (NAS:IRTC) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

iRhythm Technologies's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=111.91/-15.402821625043
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


iRhythm Technologies Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of iRhythm Technologies's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


iRhythm Technologies (iRhythm Technologies) Business Description

Traded in Other Exchanges
Address
699 8th Street, Suite 600, San Francisco, CA, USA, 94103
iRhythm Technologies Inc is a commercial-stage digital healthcare company redefining the way cardiac arrhythmias are clinically diagnosed by combining wearable biosensing technology with cloud-based data analytics and machine-learning capabilities. The company's portfolio include ambulatory cardiac monitoring services on a platform, called the Zio service, which combines an easy-to-wear and unobtrusive biosensor that can be worn for up to 14 consecutive days with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company derived its revenue from the United States.
Executives
Daniel G. Wilson officer: EVP, Strategy Corp Dev Inv Rel 699 8TH STREET, SUITE 600, SAN FRANCISCO CA 94103
Patrick Michael Murphy officer: CLO & EVP RA/QA MrktAcs & Gov 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Mervin Smith officer: EVP Strategic Business Ops C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Marc W. Rosenbaum officer: Chief Accounting Officer 7475 LUSK BLVD., SAN DIEGO CA 92121
Brice Bobzien officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Chad Patterson officer: Chief Commercial Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121
Minang Turakhia officer: EVP, CMO & CSO C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH ST #600, SAN FRANCISCO CA 94103
Quentin S. Blackford director, officer: President and CEO 7475 LUSK BLVD., SAN DIEGO CA 92121
Mojdeh Poul director 3M COMPANY OFFICE OF GENERAL COUNSEL, 3M CENTER, ST PAUL MN 55144-1000
Brian B Yoor director 100 ABBOTT PARK ROAD, AP6A-2, D-032L, ABBOTT PARK IL 60064
Mark J. Day officer: EVP, Research & Development C/O IRHYTHM TECHNOLOGIES, INC., 650 TOWNSEND STREET, SUITE 500, SAN FRANCISCO CA 94103
Douglas Devine officer: Chief Financial Officer C/O IRHYTHM TECHNOLOGIES, INC., 699 8TH STREET, SUITE 600, SAN FRANCISCO CA 94103
Bairey Merz Cathleen Noel director 16664 CUMBRE VERDE COURT, PACIFIC PALISADES CA 90272
Reyna M Fernandez officer: EVP, Chief HR Officer C/O INTERSECT ENT, INC., 1555 ADAMS DRIVE, MENLO PARK CA 94025
Sumi Shrishrimal officer: EVP, Chief Risk Officer 6340 SEQUENCE DRIVE, SAN DIEGO CA 92121

iRhythm Technologies (iRhythm Technologies) Headlines

From GuruFocus